Welcome to our dedicated page for EASTMAN CHEMICAL CO SEC filings (Ticker: EMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on EASTMAN CHEMICAL CO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into EASTMAN CHEMICAL CO's regulatory disclosures and financial reporting.
Mark J. Costa, CEO and Board Chair of Eastman Chemical Company (EMN), purchased 7,400 shares of the company's common stock on 08/27/2025 at a price of $67.89 per share. After the transaction, Mr. Costa beneficially owned 453,986 shares directly and an additional 3,153 shares indirectly through an ESOP. The Form 4 was signed by Mark D. Austin by power of attorney on 08/28/2025.
The filing records a routine insider purchase rather than a sale or derivative activity; no options, warrants, or other derivative transactions are reported. The disclosure shows the reporting person's roles as Director and CEO & Board Chair, confirming insider status and materiality for investor monitoring of executive transactions.
Capital Research Global Investors filed a Schedule 13G/A reporting beneficial ownership of 4,246,293 shares of Eastman Chemical Company common stock, representing 3.7% of the 115,459,908 shares believed outstanding. The filing lists the holder as Capital Research Global Investors, a division of Capital Research and Management Company, and provides issuer and filer addresses.
The filing certifies the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. The document is signed by Jae Won Chung on behalf of Capital Research Global Investors with a signature date of 08/05/2025.
Eastman Chemical (NYSE:EMN) filed a Form 8-K announcing the appointment of Damon Audia to its Board of Directors effective June 27 2025. Audia will serve until the 2026 Annual Meeting and join the Audit, Finance, and Environmental, Safety & Sustainability committees. Compensation will follow the standard non-employee director package disclosed in the 2025 proxy. The company confirmed no related-party transactions or family relationships. A press release detailing the appointment was furnished as Exhibit 99.1. No other material changes were reported.